ACTIVE COLLABORATIONS

UdeS_nouveau_blanc72dpi.png
UdeS_nouveau_blanc72dpi.png
UdeS_nouveau_blanc72dpi.png
Univ SA logo.jpeg
Queens Uni logo.png

ERIC MARSAULT (Université de Sherbrooke)

EXPERTISE: Medicinal and conjugation chemistry. Collaborate in the development of novel payloads for antibody-drug conjugates

STEVE JEAN (Université de Sherbrooke)

EXPERTISE: Endosomal molecular mechanism. Collaborate in the development of proteomic techniques to study intracellular transport of antibody-drug conjugates.

BRIGITTE GUERIN (Université de Sherbrooke)

EXPERTISE: Radiochemistry. Collaborate in the development of radioimmunoconjugates.

ANGEL LOPEZ (University of South Australia)

EXPERTISE: Cytokine receptor biology. Collaborate in the development of novel cytokine receptors as targets for antibody-drug conjugates and radioimmunoconjugates.

ANDREW CRAIG (Queen's University)

EXPERTISE: Tumor receptor biology. Collaborate in the development of improving intracellular access of antibody-drug conjugates.

logo-heidelberg-pharma.png

HEIDELBERG PHARMA

EXPERTISE: Antibody-drug conjugate biopharmaceutical company. Collaborate in the development of antibody-drug conjugates armed with proprietary payloads against RNA polymerase II.

Uni Helsinki logo.png

HEIKKI JOENSUU (University of Helsinki)

EXPERTISE: Gastric cancer. Collaborate in the development of novel anti-HER2 antibody-drug conjugates for gastric and breast cancer.

INTERESTED IN COLLABORATING?

We're interested in areas involving:

  •  Interesting tumor receptors 

  • Interesting cytotoxins

  • Intracellular targets that are currently 'undruggable' using traditional small molecule approaches 

  • Gene therapy and vaccines

  • Targeted therapy using radionuclides that emit short-range Auger electrons or alpha-particles 

Small Title

Humphrey Fonge (University of Saskatchewan)

EXPERTISE: Theranostic and alpha-particle developemnt for improved targeted radiation.